Table 3. Univariate and multivariate analysis of the prognostic factors for OS in the entire cohort.
| Characteristics | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age, years | |||||
| <65 | 1 | 1 | |||
| ≥65 | 1.429 (1.155–1.769) | 0.001* | 1.124 (0.892–1.416) | 0.322 | |
| Gender | |||||
| Male | 1 | ||||
| Female | 1.041 (0.832–1.302) | 0.727 | |||
| Smoking | |||||
| Never | 1 | ||||
| Yes or ever | 0.910 (0.723–1.144) | 0.417 | |||
| ECOG PS score | |||||
| 0–1 | 1 | 1 | |||
| ≥2 | 1.612 (1.229–2.113) | 0.001* | 1.373 (1.036–1.820) | 0.028* | |
| Pathology | |||||
| SCLC | 1 | 1 | |||
| Mixed-SCLC | 2.243 (1.107–4.546) | 0.025* | 2.724 (1.337–5.578) | 0.006* | |
| First-line response | |||||
| PR + CR | 1 | ||||
| SD + PD | 1.246 (0.964–1.611) | 0.093 | |||
| Liver metastases | |||||
| Only liver | 1 | 1 | |||
| Involved other organs | 1.351 (1.083–1.687) | 0.008* | 1.206 (0.953–1.525) | 0.119 | |
| Brain metastases | |||||
| No | 1 | ||||
| Yes | 1.274 (0.900–1.804) | 0.171 | |||
| Bone metastases | |||||
| No | 1 | ||||
| Yes | 1.051 (0.849–1.302) | ||||
| Intrapulmonary metastasis | |||||
| No | 1 | ||||
| Yes | 1.301 (0.967–1.752) | 0.082 | |||
| Malignant pleural effusion | |||||
| No | 1 | 1 | |||
| Yes | 1.412 (1.035–1.926) | 0.029* | 1.261 (0.892–1.781) | 0.189 | |
| Number of involved metastatic organs | |||||
| <3 | 1 | ||||
| ≥3 | 1.241 (0.970–1.586) | 0.085 | |||
| N-stage | |||||
| N0 | 1 | ||||
| N1 | 0.894 (0.325–2.463) | 0.829 | |||
| N2 | 0.926 (0.544–1.576) | 0.777 | |||
| N3 | 1.097 (0.641–1.859) | 0.747 | |||
| Treatment | |||||
| No treatment | 1 | 1 | |||
| Systemic treatment | 0.339 (0.252–0.455) | <0.001* | 0.365 (0.267–0.498) | <0.001* | |
| Systemic treatment + local radiotherapy | 0.269 (0.189–0.383) | <0.001* | 0.308 (0.211–0.450) | <0.001* | |
*, P<0.05. OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; SCLC, small cell lung cancer; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease.